Multiple myeloma (MM) is a cancer of plasma cells that has been extensively studied in
recent years, with researchers increasingly focusing on the role of microRNAs (miRNAs) in …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

MicroRNAs (miRNAs) are small noncoding RNAs that typically inhibit the translation and
stability of messenger RNAs (mRNAs), controlling genes involved in cellular processes such …

Over the past several years it has become clear that alterations in the expression of
microRNA (miRNA) genes contribute to the pathogenesis of most—if not all—human …

In normal cells multiple microRNAs (miRNAs) converge to maintain a proper balance of
various processes, including proliferation, differentiation and cell death. miRNA …

BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but
little is known about the putative mechanisms by which the BM microenvironment plays an …

Every year more than 13 million deaths worldwide are due to environmental pollutants, and
approximately 24% of diseases are caused by environmental exposures that might be …

MicroRNAs have a revolutionary impact on cancer research over recent years. They emerge
as important players in tumorigenesis, leading to a paradigm shift in oncology. The …

In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is
rarely detected at diagnosis. Using small-molecule inhibitors of MDM2, we provide evidence …

Hematologic malignancies are one of the most common cancers, and the incidence has
been rising in recent decades. The clinical and molecular features of hematologic …